This Phase II hybrid decentralized trial will examine the effect of daratumumab-based quadruplet treatment-for-multiple-myeloma-induction-therapy/" >induction therapy administered at an attenuated schedule in subjects with newly diagnosed multiple myeloma (NDMM) who are eligible for standard-of-care autologous stem cell transplantation (ASCT). Daratumumab, lenalidomide, bortezomib, and dexamethasone (Dara-RVd) have recently become a standard induction regimen for patients with NDMM who are eligible for ASCT in the United States. As implemented in clinical trials, Dara-RVd involves twice weekly bortezomib administration, which is inconvenient for patients and may result in increased rates of limiting toxicity, such as peripheral neuropathy. Adoption of alternate schedules involving once-weekly bortezomib is common in real-world practice, however a paucity of prospective data supporting this practice exists.
This study examines the efficacy of an attenuated Dara-RVd schedule involving once-weekly bortezomib dosing.
Written informed consent was obtained to participate in the study and HIPAA authorization for release of personal health information. Subjects are willing and able to comply with study procedures based on the judgment of the investigator. Age ≥18 years at the time of consent. Eastern Cooperative Oncology Group (ECOG) ≤ 2 Subjects with Multiple Myeloma.
Exclusion Criteria:
Active infection requiring systemic therapy or other serious infection within 14 days prior to study treatment. Pregnant or breastfeeding.
